Exact Sciences Corporation
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
About
CEO
Mr. Kevin T. Conroy J.D.
Employees
6,500
Instrument type
Common Stock
Sector
Healthcare
Industry
Diagnostics & Research
MIC code
XNCM
Address
5505 Endeavor Lane, Madison, WI 53719, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 3, 2025 | — | — | — | — |
| Jul 29, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 19, 2025 | -0.29 | — | — | — |
| Nov 6, 2024 | -0.21 | -0.21 | 0.00 | 0.00% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 9 |
| Average estimate | — | -0.23 | — | 0.00 |
| Low estimate | — | -0.52 | — | -0.79 |
| High estimate | — | 0.22 | — | 0.97 |
| Last year EPS | — | -0.54 | — | -0.57 |
[stock_revenue_estimate]
Growth estimates
Current qtr
56.510%
Next qtr. (Mar 2025)
57.920%
Current year
63.630%
Next year (Dec 2025)
99.940%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 2.50B | 2.08B | 1.77B | 1.49B | 876.29M |
| Cost of revenue | 654.20M | 574.40M | 458.76M | 354.30M | 216.72M |
| Gross profit | 1.85B | 1.51B | 1.31B | 1.14B | 659.58M |
| Operating expense | |||||
| Research & development | 425.88M | 393.42M | 385.65M | 554.05M | 139.69M |
| Selling general and admin | 1.62B | 1.58B | 1.66B | 1.07B | 737.63M |
| Other operating expenses | -78.43M | 13.24M | — | -23.67M | — |
| Operating income | -214.35M | -577.53M | -835.47M | -558.01M | -233.78M |
| Non operating interest income | |||||
| Income | — | — | — | — | 131,000 |
| Expense | 24.42M | 13.91M | 12.88M | 11.82M | 8.73M |
| Other income expense | 42.42M | -35.39M | 11.57M | -253.91M | -161.17M |
| Pretax income | -201.75M | -632.57M | -842.51M | -829.06M | -406.44M |
| Tax provision | 2.40M | -9.06M | -246.88M | -5.46M | -193.35M |
| Net income | -204.15M | -623.51M | -595.63M | -823.61M | -213.09M |
| Basic EPS | -1.13 | -3.54 | -3.48 | -5.61 | -0.64 |
| Diluted EPS | -1.13 | -3.54 | -3.48 | -5.61 | -0.64 |
| Basic average shares | 180.14M | 176.35M | 171.35M | 151.14M | 131.26M |
| Diluted average shares | 180.14M | 176.35M | 171.35M | 151.14M | 131.26M |
| EBITDA | -13.13M | -385.71M | -660.85M | -399.97M | -186.30M |
| Net income from continuing op. | -204.15M | -623.51M | -595.63M | -823.61M | -213.09M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 6.47B | 6.23B | 6.68B | 4.93B | 3.51B |
| Current assets | |||||
| Cash | 530.10M | 178.17M | 247.34M | 901.29M | 146.93M |
| Cash equivalents | 75.28M | 64.33M | 68.14M | 589.99M | 30.32M |
| Cash and cash equivalents | 605.38M | 242.49M | 315.47M | 1.49B | 177.25M |
| Other short term investments | 172.27M | 389.56M | 715.01M | 348.70M | 146.40M |
| Accounts receivable | 203.62M | 158.04M | 216.65M | 233.19M | 130.36M |
| Other receivables | — | — | — | — | — |
| Inventory | 127.48M | 118.26M | 104.99M | 92.27M | 61.72M |
| Prepaid assets | — | — | 74.12M | 33.16M | 38.20M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 85.63M | 73.90M | 74.12M | 33.16M | 38.20M |
| Non current assets | |||||
| Properties | 143.71M | 167.00M | 363.97M | 268.06M | 230.45M |
| Land and improvements | 11.45M | 11.13M | 9.92M | 9.33M | 6.23M |
| Machinery furniture equipment | 494.18M | 423.29M | 137.41M | 100.49M | 79.86M |
| Construction in progress | 104.59M | 68.40M | 100.34M | 18.75M | 149.69M |
| Leases | 214.56M | 200.59M | 147.08M | 117.87M | 80.35M |
| Accumulated depreciation | -417.20M | -307.59M | -214.82M | -137.54M | -77.63M |
| Goodwill | 6.62B | 6.65B | 6.76B | 3.32B | 3.55B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 1.89B | 1.96B | 2.09B | 847.12M | 1.14B |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 177.39M | 90.58M | 74.59M | 63.77M | 23.32M |
| Total liabilities | 3.33B | 3.18B | 3.30B | 2.69B | 1.22B |
| Current liabilities | |||||
| Accounts payable | 78.82M | 74.92M | 67.83M | 35.71M | 25.97M |
| Accrued expenses | 94.06M | 97.96M | 215.04M | 108.95M | 98.16M |
| Short term debt | 79.38M | 28.37M | 19.71M | 325.52M | 8.73M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 247.62M | 201.25M | 183.52M | 124.65M | 95.17M |
| Other current liabilities | 14.82M | 10.25M | 30.97M | 38.27M | 8.47M |
| Non current liabilities | |||||
| Long term debt | 2.48B | 2.42B | 2.36B | 2.01B | 946.30M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 335.98M | 352.46M | 417.78M | 51.34M | 34.91M |
| Shareholders equity | |||||
| Common stock | 1.82M | 1.78M | 1.74M | 1.60M | 1.48M |
| Retained earnings | -3.47B | -3.27B | -2.64B | -2.05B | -1.12B |
| Other shareholders equity | 1.43M | -5.24M | -1.44M | 526,000 | -100,000 |
| Total shareholders equity | 3.15B | 3.04B | 3.39B | 2.24B | 2.29B |
| Additional paid in capital | 6.61B | 6.31B | 6.03B | 4.28B | 3.41B |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||
| Net Income | -204.15M | -623.51M | -595.63M | -823.61M | -213.09M | -175.15M | -114.40M | -167.21M | -157.80M | -100.05M | -46.51M | -52.42M | -28.68M | -11.56M | -9.13M | -9.74M | -11.96M | -12.92M | -14.52M | -18.52M | -28.34M | -29.88M | -23.49M | -11.88M | -4.96M |
| Depreciation | 206.61M | 197.56M | 180.35M | 163.36M | 50.25M | 23.08M | 15.56M | 11.51M | 7.75M | 3.71M | 1.42M | 985,000 | 411,000 | 230,000 | 175,000 | 626,000 | -2.24M | -3.01M | -2.93M | -2.52M | -62,000 | 2.16M | 1.07M | 404,000 | 424,285 |
| Deferred Taxes | -955,000 | -11.90M | -253.17M | -6.75M | -193.61M | — | -115,000 | 800,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 231.31M | 206.82M | 253.06M | 152.91M | 108.48M | 60.26M | 35.51M | 23.73M | 18.05M | 11.52M | 7.74M | 5.49M | 3.96M | 2.12M | 2.63M | 1.01M | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | -62.55M | -17.14M | 205.17M | 429.51M | 3.67M | 26.17M | -1.62M | -961,000 | -529,000 | -294,000 | -4.14M | -2.99M | -4.04M | -5.21M | 1.78M | 66,000 | 2.81M | 3.01M | — | — | — | — | — | 2,000 | 13,780 |
| Accounts Receivable | -43.42M | 61.09M | 25.15M | -100.53M | -27.63M | -17.29M | -17.53M | -3.59M | -3.56M | -1.38M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Accounts Payable | — | — | — | — | — | 11.33M | 15.38M | -2.60M | 661,000 | 1.89M | -2.89M | 2.89M | -263,000 | 873,000 | -528,000 | 438,000 | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -39.68M | -36.69M | -83.84M | 3.09M | -29.39M | -16.70M | -20.69M | -468,000 | -3.21M | -4.50M | 2.66M | — | — | -988,000 | -2.46M | 899,000 | 2.35M | 301,000 | -738,000 | 481,000 | 14.09M | 15.06M | 2.18M | -83,000 | — |
| Operating Cash Flow | 87.17M | -223.77M | -268.91M | -182.01M | -301.32M | -88.29M | -87.90M | -138.79M | -138.64M | -89.11M | -41.73M | -46.05M | -28.60M | -14.53M | -7.53M | -6.70M | -9.05M | -12.62M | -18.18M | -20.57M | -14.32M | -12.67M | -20.24M | -11.56M | -4.53M |
| Investing Activities | |||||||||||||||||||||||||
| Capital Expenditures | -124.19M | -214.46M | -135.77M | -65.08M | -172.65M | -150.09M | -48.48M | -14.85M | -20.08M | -11.99M | -8.75M | -681,000 | -2.12M | -626,000 | -462,000 | 270,000 | -124,000 | -394,000 | -227,000 | -287,000 | -2.56M | -1.34M | -2.62M | -763,000 | -292,183 |
| Net Intangibles | — | — | — | — | — | -578,000 | -20.69M | — | -1.90M | — | — | — | — | — | — | -100,000 | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | -68.98M | -57.51M | -517.77M | -22.61M | -973.86M | -17.91M | -2.98M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -139.85M | -131.49M | -1.16B | -1.09B | -634.12M | -1.19B | -357.05M | -189.99M | -205.05M | -209.47M | -98.51M | -96.05M | -87.02M | -24.50M | -18.88M | -3.46M | -20.69M | -31.38M | -24.28M | -74.16M | -11.01M | -26.35M | — | — | — |
| Sale of Investments | 382.95M | 453.07M | 794.32M | 886.68M | 1.66B | 578.79M | 271.47M | 193.32M | 162.28M | 104.17M | 72.29M | 58.41M | 45.73M | 10.20M | 16.47M | 11.54M | 28.85M | 36.30M | 40.42M | 50.47M | 23.75M | — | — | — | — |
| Investing Cash Flow | 49.68M | 74.07M | -1.08B | -702.04M | -124.43M | -782.30M | -140.12M | -11.52M | -62.86M | -117.29M | -34.97M | -38.32M | -43.41M | -14.92M | -2.87M | 8.35M | 8.04M | 4.53M | 15.76M | -24.14M | 9.47M | -28.10M | -4.57M | -1.08M | -721,568 |
| Financing Activities | |||||||||||||||||||||||||
| Long-Term Debt Issuance | 137.98M | 50.00M | — | 1.13B | 729.48M | 920.67M | — | — | 5.06M | 2.40M | — | — | — | — | 1.00M | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | -23.75M | -151.30M | -493.36M | — | -376,000 | -166,000 | -404,000 | -351,000 | -333,000 | -107,000 | — | — | — | — | — | — | — | — | — | — | — | — | -6,405 |
| Other Financing Charges | -9.75M | -5.53M | -5.29M | -1.76M | -123,000 | 1.95M | -202,000 | — | — | — | — | — | — | 2.40M | 16.75M | 100,000 | 100,000 | 220,000 | -5,000 | — | — | 248,000 | — | 82,000 | 4,072 |
| Financing Cash Flow | 128.23M | 44.47M | -29.04M | 1.83B | 236.00M | 922.61M | 252.81M | 144.08M | 178.80M | 240.63M | 72.96M | 57.65M | 27.22M | 84.72M | 31.81M | 100,000 | 386,000 | 473,000 | 132,000 | 43.57M | 1.10M | 615,000 | 50.78M | 31.99M | 56,684 |
| Other Cash Details | |||||||||||||||||||||||||
| End Cash Position | 609.68M | 242.79M | 315.77M | 1.49B | 177.53M | 160.43M | 77.49M | 48.92M | 41.14M | 58.13M | 12.85M | 13.35M | 35.78M | 78.75M | 21.92M | 4.94M | 4.49M | 4.83M | 11.99M | 13.09M | 14.20M | 17.44M | 56.84M | 26.47M | 3.55M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 18.78M | 11.52M | 10.74M | 9.38M | 5.13M | 4.64M | 201,000 | 209,000 | 95,000 | 29,000 | 48,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 31.93M | -438.02M | -238.00M | 71.40M | -284.31M | -219.03M | -140.89M | -144.92M | -156.00M | -93.45M | -49.03M | -45.20M | -29.58M | -14.07M | -13.10M | -8.01M | -8.90M | -12.55M | -16.21M | -21.20M | -16.43M | -13.25M | -18.45M | -8.75M | -4.90M |
Error: Invalid format in Holders JSON file.
Article
Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing
NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research, and Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced a strategic partnership aimed at accelerating clinical evidence generation for Exact Sciences' molecular residual disease test (MRD), OncodetectTM. The partnership leverages Flatiron's leading-edge clinical research platform to study a broad range of solid tumor types.
Feb 5, 2025
Article
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date.
Feb 3, 2025
Article
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) meeting January 23-25, 2025, in San Francisco. “The data we are presenting at ASCO GI underscore Exact Sciences' leadership in advancing scientific innovation to drive meaningful progress in cancer detection and patient care,” said Jorge Garces, PhD, ch.
Jan 21, 2025
